Noteworthy - Pharmaceutical Executive



"Market-Based" Price Controls in India?

April 2, 2014

Ram Subramanian, Nikhil Mutyal and Emma Nechamkin outline three strategic implications for pharma pricing strategies in India

Musings from the Conference Circuit: A Wake-up Call for Pharma

March 28, 2014

Bill Drummy reports on the key healthcare takeaways from this year's South by Southwest (SXSW) Interactive conference in Austin, Texas.

Italian Ruling on Roche and Novartis Resonates Across Europe

March 24, 2014

Roche and Novartis have been fined in Italy on pricing conspiracy charges, fueling a wider debate in Europe about expenditure, efficiency and off-label prescribing.

Manufacturers Struggle with FDA's "Breakthrough Drug" Development

March 21, 2014

Accelerated testing and production create challenges in documenting product quality, writes Jill Wechsler.

Population Health: The Call to Community

March 11, 2014

Population health is the foundation for much of what is truly new in US health reform. Pharm Exec talks to Dr. David Nash, Dean of the Jefferson Medical University School of Population Health.

What Do Pharma's "High Performers" Have in Common?

March 7, 2014

A study of high-performing pharma companies reveals science-based innovation strategies and patient-outcome-based commercial models are now the key drivers of growth.

The New Metrics of Market Success

March 3, 2014

Profitability now depends on metrics to help companies answer a key strategic question: "stay the course" with more investment in sales and marketing? Or "stand down" and deploy those scarce assets somewhere else?

Pharm Exec: Annual Press Audit 2014

March 3, 2014

Pharm Exec's latest survey of press issues shows that media coverage continues to remain on balance negative toward the industry, by a slight margin: 47% this year compared to a 46% average over the last seven years.

The Push for Transparency: Risks, Costs, and Concerns

February 26, 2014

The growing clamor for broader access to information on health care practices, policies and costs is affecting research, marketing and compliance, writes Jill Wechsler.


Click here